ParkinsonCanadaV1, PascalFrancis, Checkpoint, bibRecord, 000917

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Identifieur interne : 000917 ( PascalFrancis/Checkpoint ); précédent : 000916; suivant : 000918

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Auteurs : Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]

Source :

Annals of neurology [ 0364-5134 ] ; 2003.

RBID : Pascal:03-0498653

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Ropinirole, Tomoscintigraphie, Dopa, Dopamine, Putamen, Cartographie, Etude comparative, Lévodopa, Positon, Stimulant dopaminergique, Etude double insu, Homme, Pronostic, Agoniste, Récepteur dopaminergique D2, Aminoacide, Catécholamine, Captation.
Wicri :
- topic : Cartographie, Homme.

English descriptors

KwdEn :
- Agonist, Aminoacid, Cartography, Catecholamine, Comparative study, D2 Dopamine receptor, Dopa, Dopamine, Dopamine agonist, Double blind study, Emission tomography, Human, Levodopa, Parkinson disease, Positron, Prognosis, Putamen, Ropinirole, Uptake.

Abstract

Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using ¹⁸F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and ¹⁸F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen ¹⁸F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in ¹⁸F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by ¹⁸F-dopa PET.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000A43
to stream PascalFrancis, to step Curation: 000280

Links to Exploration step

Pascal:03-0498653

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université McMaster</orgName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of South Florida and Tampa General Healthcare</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0498653</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0498653 INIST</idno>
<idno type="RBID">Pascal:03-0498653</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A43</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000280</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000917</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000917</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université McMaster</orgName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of South Florida and Tampa General Healthcare</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Aminoacid</term>
<term>Cartography</term>
<term>Catecholamine</term>
<term>Comparative study</term>
<term>D2 Dopamine receptor</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Dopamine agonist</term>
<term>Double blind study</term>
<term>Emission tomography</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Prognosis</term>
<term>Putamen</term>
<term>Ropinirole</term>
<term>Uptake</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Ropinirole</term>
<term>Tomoscintigraphie</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Putamen</term>
<term>Cartographie</term>
<term>Etude comparative</term>
<term>Lévodopa</term>
<term>Positon</term>
<term>Stimulant dopaminergique</term>
<term>Etude double insu</term>
<term>Homme</term>
<term>Pronostic</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Aminoacide</term>
<term>Catécholamine</term>
<term>Captation</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cartographie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using <sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and <sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen <sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in <sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by <sup>18</sup>
F-dopa PET.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>54</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WHONE (Alan L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WATTS (Ray L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>STOESSL (A. Jon)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DAVIS (Margaret)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RESKE (Sven)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NAHMIAS (Claude)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RIBEIRO (Maria J.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>REMY (Philippe)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>POEWE (Werner H.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>BROOKS (David J.)</s1>
</fA11>
<fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>REAL-PET Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>93-101</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000119867680110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0498653</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using <sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and <sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen <sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in <sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by <sup>18</sup>
F-dopa PET.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cartographie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cartography</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cartografía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Positon</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Positron</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Positrón</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>22</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Homme</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Human</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Hombre</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Agonist</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Agonista</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>26</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Aminoacide</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Aminoacid</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Aminoácido</s0>
<s5>27</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>28</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>28</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>28</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Captation</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Uptake</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Captación</s0>
<s5>35</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>335</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Allemagne</li>
<li>Autriche</li>
<li>Canada</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Bade-Wurtemberg</li>
<li>District de Tübingen</li>
<li>Grand Londres</li>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Ontario</li>
<li>Tyrol (Land)</li>
</region>
<settlement><li>Hamilton (Ontario)</li>
<li>Innsbruck</li>
<li>Londres</li>
<li>Orsay</li>
<li>Toronto</li>
<li>Toulouse</li>
<li>Ulm</li>
</settlement>
<orgName><li>Université McMaster</li>
<li>Université d'Ulm</li>
<li>Université de Toronto</li>
<li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
</region>
<name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
</country>
<country name="États-Unis"><noRegion><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
</noRegion>
<name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</country>
<country name="Canada"><noRegion><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</noRegion>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
</region>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</region>
<name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
</country>
<country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000917 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000917 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:03-0498653
   |texte=   Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri